A recent review published in Clinical and Experimental Rheumatology outlines a three-stage framework for identifying psoriatic arthritis before permanent bone and joint damage occurs. While roughly 20% to 30% of patients with psoriasis eventually develop this condition, the research indicates that over 80% of those cases pass through a silent period of immune activation that often goes unmonitored during standard dermatological exams.
The authors categorize the transition from skin disease to arthritis as a continuum. The at-risk phase features systemic immune activation but lacks musculoskeletal symptoms. In the subclinical phase, patients may experience joint pain or show signs of inflammation on imaging, yet they do not meet the formal criteria for arthritis. The final clinical phase is confirmed when synovitis, enthesitis, or dactylitis becomes apparent.
Predictors for this progression include the severity of the initial skin condition, family history, and the presence of nail disease. Because dermatologists rarely screen for these indicators, many patients miss the opportunity for early intervention.
Related: Lung Cancer Task Force Maps Roadmap to Close Survival Gap
Clinicians could potentially alter the long-term prognosis for a significant portion of the patient population by shifting the focus to high-risk profiles rather than waiting for overt physical changes.
Experts examined evidence from 82 studies published between 2000 and 2025 to determine how to better identify those at risk. These investigators found that ultrasonography and MRI can detect inflammation in patients who have no outward joint symptoms. Emerging PET imaging using a fibroblast-activation tracer has also shown promise in spotting abnormal signals at joint sites before other imaging modalities.
Several validated screening questionnaires are available to help bridge the gap between dermatology and rheumatology. The Psoriasis Epidemiology Screening Tool, ToPAS-2, and EARP are among the primary instruments used to flag patients. Reporters citing the National Psoriasis Foundation mention that 41% of patients who screened positive via PEST had not previously received a diagnosis, suggesting that regular, standardized testing could capture cases that currently slip through the cracks of routine care.
Related: Brain Undergoes Major Change at Thirty Two
Observational data suggests that treating psoriasis with biologic medication may lower the risk of developing PsA.
Despite these findings, the authors emphasize that definitive prevention trials are still needed. Current evidence relies heavily on observational cohorts rather than randomized controlled trials. Without a validated biomarker or specific imaging threshold to predict who will progress, the medical community remains cautious about universal intervention. The report advocates for closer coordination between specialists for patients exhibiting high-risk phenotypes like scalp or nail involvement.
